VVUS has the lowest Price to Sales and Price to Earnings percentile on the entire industry, at the same time has the very best percentile for Gross Profit and Operating margins in the entire industry…You can not say its all the ANDA’s fault that PPS is so low. Can you say its all DEBT? Time to do something about that!!!!!!!!!!!
Ruprecht has emphasized that Qsymia is the best weight loss drug on the market, keep in mind that VVUS has been working on deals for the licensing of Stendra in Mexico and Latin America. Those deals could bring VVUS as much as 100 million dollars in up front payments in my opinion. VVUS is also working on a deal for Spedra licensing in Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia, this could easily bring VVUS another 100 million plus dollars in up front payments. Then there are the supply agreements in place that also generates revenue for VVUS. The new PAH drug that VVUS has recently bought the license for is due to start trials, I believe by the end of 2017. VVUS is looking to buy or merge with another Parma as well. With nearly 300 million dollars in cash and assets and another possible 200 million dollars from Stendra/spedra licenses VVUS would have nearly a half a billion dollars in cast to operate with. I will continue my purchases while I can and hold for the long term.
Somebody throw the life jackets in this ship is sinking fast,even the paid pumpers are giving up hope R.I.P.
SELL ARNA and buy vvus.
For technical confirmation! The beat down is in tact and no updates from Fischer. New shares are getting pounded down in true VVUS fashion. They stopped the technical build up just as I predicted. It would have taken some fresh PR from VVUS to complete the build up but nothing for now. The retrace is deep as usual.
Ruprecht...QSYMIA is an anti-obesity medicine in the newly accepted disease category OBESITY...not to be confused with a diet drug or weight loss supplement. Q is serious medicine for a serious disease.
Looks like all 6 cents were given back after hours. Well, THAT excitement was short-lived!
IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!
2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .Load up guys before she the MEGA news hit the wire and thank me later .GL
MarketCap $50 Million Cash ~$12 Million (including convertible debt) =cash untill 2021+ Price: 0.80
NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July NDA resubmission for Rizaport (migraine) in early Q3 Partnership for Tadalafil in 2H 2017
IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.
Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.
ARNA has REVERSE split 1 for 10 and I had posted here that ARNA was going to do this and Ruprecht and his moody alias friends attacked me for that writing and they denied that it was going to happen. It has happened and now that makes ARNA and OREX as the two competitor who have reverse split. ARNA is going to be shorted down to 1 dollar in my opinion and ultimately they will be gone from the markets. VVUS has been managed much better as all obesity drugs have been struggling. Yet, VVUS has the strongest balance sheet and has also has the strongest revenue and VVUS has been profitable. So, all those who have attacked VVUS and claimed that VVUS was the weakest of the three have all been proven wrong! VVUS is in the best position of all in this sector in my opinion and VVUS has the best weight loss drug on the market.
Ruprecht is in PANIC mood!!!!! PANIC, PANIC, PANIC!!!!!!! Stay short Ruprecht, keep spending your bosses money! Sammy keep helping Ruprecht!!!! hahaha
So now we are gifted with an ALLEGED prescribing doctor on this MB. No doubt, this quack has, or will, prescribe our garbage Qsymia to his victims. And his reports to us? --GLOWING! A MIRACLE! PENICILLIN re-invented! Gold, and Riches!! And the stock a year from now?
...and yet, the lone and level sands stretched far and wide...
Fidelity news came out with the news analytic of score 1.4 means positive. This is why this stock is up after hours.
I want to give a big shout out to Ted and say thanks for the tip on DCTH bought at .08 and sold at .29.THE MOOKY KOOKY TWIST OH YEAH THE MOOKY KOOKY TWIST.
Qsymia Works better
Lose 4 times more weight than diet and exercise alone
Lose 24lbs or more and keep it off
Achieve almost 10% weight loss
Lose 4 inches off your belt line
Some expectations affecting near term price in 2017---A new PAH formula patented to VVUS, Qsymia marketed widely for sleep aphnea, General upswing in qsymia sales with a down ratchet in cost affecting the quarterly earnings and creating a positive surprise, and a spendra license deal coming to fruition.
This MB gets an overload of wrong information put out by Ruprecht about generics. Please read for yourselves what the true status is:
VIVUS Announces Favorable Markman Ruling in Qsymia(R) Patent Litigation
MOUNTAIN VIEW, CA--(Marketwired - July 21, 2016) - VIVUS, Inc. (NASDAQ: VVUS) today announced that the United States District Court for the District of New Jersey has issued a claim construction (Markman) ruling governing patent litigation brought by
Ruprecht's 3 day plan didn't work out, even with Sammy the Mule selling his shares and help Ruprecht disparage VVUS management. Load up and load long is my view.
Vvus unfortunately continues its decline from its recent spurt upwards, it is going to take some materially positive news to get a sustainable move up (Latin deal with continuing revenue stream, lawsuits resolution, Q deal, etc.). At the glacial pace that Senile Seth and clowns move, it might be quite some time before we catch a break (Seth has been promising the Latin deal for several years now and did so again in our last CC). Although my assertion will undoubtedly draw a withering tirade from WebKevin(+), to the rest of us rational board members the truth in my assertion is self evident based on a LONG stay at a bucket when the market is at all time HIGHS.
Can someone explain why the drop in sales in the last 3-4 years? is it all because of the ANDA issue??
Oh oh Ruprecht, your last move didn't work! Try again Mr. talking points. Sammy the Mule is helping diligently but you are struggling mightily.